一期前路病灶清除、后路内固定并横突间植骨融合治疗胸腰椎结核

目的:评价一期前路病灶清除、后路内固定并横突间植骨融合治疗胸腰椎结核的临床疗效。方法:采用一期前路病灶清除、后路内固定并横突间植骨融合手术治疗胸、腰椎结核患者17例,按照Frankel分级评定患者手术前后的神经功能,根据X线片评价植骨融合时间,测量术前、术后后凸角度及随访期内的角度丢失。结果:17例患者结核病灶清除彻底,切口均Ⅰ期愈合、无窦道形成,结核治愈无复发。后凸畸形平均矫正19.2°;在随访期内,后凸畸形矫正有1°~4°丢失。X线片示植骨界面骨性融合时间平均5个月。3例出现并发症,对症处理后好转。结论:一期前路病灶清除、后路内固定并横突间植骨融合治疗胸、腰椎结核的疗效确切,具有迅速缓解症状、早期离床活动和较理想的脊柱矫形等优点,是治疗胸、腰椎结核的有效方法。     

影像设备引导下经皮穿刺与支气管填塞治疗耐多药肺结核空洞的疗效分析

目的评价影像设备引导下,经皮穿刺与经支气管填塞,治疗耐多药肺结核空洞的临床疗效。方法CR、CT及生化,病理学确诊的耐多药肺结核空洞患者88例,用经皮穿刺治疗44例(A组)和经支气管填塞治疗44例(B组)。并对照分析其方法,并发症和疗效,评估其应用价值。结果A组闭塞性空洞愈合14例(32%)、净化性空洞愈合16例(36%),无变化及轻微缩小14例(32%),总治愈率为68%;B组闭塞性空洞愈合23例(52.27%),净化空洞愈合17例(38.64%),无变化及轻微变小4例(9%),总治愈率达91%。B组比A组总疗效高出23%(91%~68%),并发症低,疗程缩短1~2个月。结论支气管填塞治疗耐多药肺结核空洞的疗效要优于经皮穿刺的方法。是目前治疗耐多药肺结核空洞的比较有效方法。     

Comparison of redox and D29 phage methods for detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis

Rapid, accurate and inexpensive methods are essential to detect drug-resistant Mycobacterium tuberculosis and allow timely application of effective treatment and precautions to prevent transmission. The proportion method, the MTT and Alamar Blue redox methods, and the D29 mycobacteriophage assay, were compared for their ability to detect resistance to isoniazid and rifampicin. When tested against a panel of known M. tuberculosis strains, the redox methods and the D29 assay showed good sensitivity and specificity compared to the proportion method, suggesting that they could be useful alternatives for identifying multidrug resistance in M. tuberculosis.     

Mycobacterium Tuberculosis Infection Incidence in Hospitalized Renal Transplant Patients in the United States, 1998–2000

The incidence, risk factors, and prognosis for Mycobacterium tuberculosis (MTB) infection have not been reported in a national population of renal transplant recipients. We performed a retrospective cohort study of 15,870 Medicare patients who received renal transplants from January 1, 1998 to July 31, 2000. Cox regression analysis derived adjusted hazard ratios (AHR) for factors associated with a diagnosis of MTB infection (by Medicare Institutional Claims) and the association of MTB infection with survival. There were 66 renal transplant recipients diagnosed with tuberculosis infection after transplant (2.5 cases per 1000 person years at risk, with some falling off of cases over time). The most common diagnosis was pulmonary TB (41 cases). In Cox regression analysis, only systemic lupus erythematosus (SLE) was independently associated with TB. Mortality after TB was diagnosed was 23% at 1 year, which was significantly higher than in renal transplant recipients without TB (AHR, 4.13, 95% CI, 2.21, 7.71, p < 0.001). Although uncommon, MTB infection is associated with a substantially increased risk of mortality after renal transplantation. High-risk groups, particularly those with SLE prior to transplant, might benefit from intensified screening.     

PCR-SSCP法检测结核分枝杆菌耐药性

目的：探讨耐多药结核分枝杆菌耐药基因突变与耐药性的关系以及聚合酶链反应-单链构象多态性分析(poly merase chain reaction-single strand cinfomlation polymorphism，PCR-SSCP)方法的临床应用价值。方法：用PCR-SSCP方法检测58株结核分枝杆菌临床分离株katG，rpoB，rpsL基因突变并与常规药敏试验检测结果进行对比。结果：经常规药敏试验检测，58株结核分枝杆菌临床分离株中共有41株耐药，其中，耐异烟肼(INH)为35株，高耐药株27株；耐利福平(RFP)为31株，高耐药株24株；耐链霉素(SM)有31株，高耐药株26株。同时耐3种药物的有21株(51．2％)，耐2种药物的14株(34．1％)，单耐药株6株(14．6％)．PCR-SSCP方法对58株临床分离株katG，rpoB，rpsL基因突变的检测率为40％(23／58)，45％(26／58)，38％(22／58)，其中检出3个基因同时突变的有13株(32％)，2种基因突变的12株(29％)，1种基因突变的有10株(23．8％)．常规药敏试验与PCR-SSCP法检出结核分枝杆菌同时耐3种药物的符合率为61．9％(13／21)，检出耐2种药物的符合率为85．70k，(12／14)，检出耐1种药物的符合率为50％(3／6)．高耐药株中突变率为80．5％(62／77)，低耐药株中突变率为60％(12／20)．结论：PCR-SS-CP方法对耐2种以上药物的结核杆菌检出率较高，且耐药基因突变率随着耐药浓度增高而增高。将PCR-SSCP法与药敏试验联合应用可互相弥补，已成为临床指导用药的好方法。     

病灶清除一期植骨内固定治疗脊柱结核

目的探讨脊柱结核病灶清除手术后内固定方式的选择。方法对35例脊柱结核患者采用3种不同术式：16例前路病灶清除、植骨,一期前路钢板或钉棒内固定;14例前路病灶清除、植骨,一期后路经弓根钉棒内固定;5例前路病灶清除、植骨,一期前路钢板、后路钉棒联合内固定。结果35例均获随访,时间18-24个月。X线显示病灶静止,植骨融合,内固定无松动断裂,后凸畸型改善,其中合并脊髓损害15例,按Frankel分级,C级3例、D级12例术后全部恢复到E级。结论病灶清除一期植骨内固定有利于重建脊柱稳定性,纠正和预防脊柱后凸畸形,可避免或减少结核复发。     

肾结核90例临床分析

目的 探讨肾结核的临床特征及有效治疗方法。方法 回顾性分析90例肾结核患者的临床资料。结果 近年来肾结核病例仍较多见，早期诊断困难，单纯药物治疗可治愈者约16％，手术切除仍是主要治疗方法。结论 不典型肾结核的发病率仍较高。尿常规、B超、静脉肾盂造影为主要诊断方法，诊断性治疗仍是确诊的重要依据。     

核素全身骨显像在脊柱结核诊治中的临床价值

[目的]评价核素全身骨显像在脊柱结核诊治中的价值。[方法]对175例脊柱结核采用99Tcm—MDP（亚锡亚甲基二膦酸盐）核素全身骨显像，了解脊柱病灶的显影情况和全身其他骨关节是否并存病灶的情况。[结果]175例患者全部显像为阳性，其中伴有多节段椎体结核者146例，其中2个椎体者78例，3个椎体者26例，4个椎体以上者42例。伴有四肢骨关节结核者22例，伴骶髂关节结核者29例。[结论]核素全身骨显像在脊柱结核诊治中有重要价值，可以发现全身骨与关节多个结核病灶，对制定脊柱结核的治疗方案有指导作用。     

Comparison of Quantiferon-TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation

Screening for latent tuberculosis infection (LTBI) is recommended prior to organ transplantation. The Quantiferon-TB Gold assay (QFT-G) may be more accurate than the tuberculin skin test (TST) in the detection of LTBI. We prospectively compared the results of QFT-G to TST in patients with chronic liver disease awaiting transplantation. Patients were screened for LTBI with both the QFT-G test and a TST. Concordance between test results and predictors of a discordant result were determined. Of the 153 evaluable patients, 37 (24.2%) had a positive TST and 34 (22.2%) had a positive QFT-G. Overall agreement between tests was 85.1% (kappa= 0.60, p < 0.0001). Discordant test results were seen in 12 TST positive/QFT-G negative patients and in 9 TST negative/QFT-G positive patients. Prior BCG vaccination was not associated with discordant test results. Twelve patients (7.8%), all with a negative TST, had an indeterminate result of the QFT-G and this was more likely in patients with a low lymphocyte count (p = 0.01) and a high MELD score (p = 0.001). In patients awaiting liver transplantation, both the TST and QFT-G were comparable for the diagnosis of LTBI with reasonable concordance between tests. Indeterminate QFT-G result was more likely in those with more advanced liver disease.